SCHEMBL16765148

SCHEMBL16765148

Nc1nc2ccc(C(F)(F)F)nn2c1C(=O)O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 1/20 0.37
AKT2 P31751 1/20 0.37
CDK2 P24941 7/20 0.34
CDK4 P11802 5/20 0.34
KDM4E B2RXH2 3/20 0.33
HSD17B10 Q99714 2/20 0.33
ALDH1A1 P00352 2/20 0.33
HPGD P15428 1/20 0.33
PTGS2 P35354 1/20 0.33
MAPT P10636 1/20 0.33
KLKB1 P03952 2/20 0.32
USP7 Q93009 1/20 0.32
PDE4B Q07343 1/20 0.32
CDK1 P06493 1/20 0.32
CCNB1 P14635 1/20 0.32
CCND1 P24385 1/20 0.32
CCNE1 P24864 1/20 0.32
MAT2A P31153 1/20 0.32
ALPL P05186 1/20 0.32
ALPI P09923 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16764299 0.83 MAPK8 (0.48) KDM4EHSD17B10ALDH1A1HPGDMAPT
SCHEMBL18816951 0.77 ALDH1A1 (0.40) AKT1AKT2CDK2CDK4KDM4E
SCHEMBL18817237 0.77 MEN1 (0.38) AKT1AKT2CDK2CDK4KDM4E
SCHEMBL21033318 0.73 MAPT (0.35) AKT1AKT2KDM4EHSD17B10ALDH1A1
SCHEMBL18365956 0.71 RIPK1 (0.44) AKT1AKT2KDM4EHSD17B10ALDH1A1
SCHEMBL12425929 0.71 AKT1 (0.37) AKT1AKT2KDM4EHSD17B10ALDH1A1
SCHEMBL21033315 0.70 PTGS1 (0.41) KDM4EHSD17B10ALDH1A1PTGS2
SCHEMBL30845864 0.70 PDE10A (0.43) AKT1AKT2KDM4EHSD17B10ALDH1A1
SCHEMBL30492134 0.67 RIPK1 (0.43) AKT1AKT2KDM4EALDH1A1ALPL
SCHEMBL167782 0.66 KDM4E (0.47) KDM4EHSD17B10ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160326180-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-11-10 US disclosed
EP-3077393-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2016-10-12 EP disclosed
US-20150158868-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED 2015-06-11 US disclosed
WO-2015084384-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150158868-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, MAP3K20, CHEK1 AKT1 76/4885AKT2 163/4885CDK2 194/4885
US-20160326180-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, MAP3K20, CHEK1 AKT1 76/4885AKT2 163/4885CDK2 194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.